Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 591 clinical trials
PEnile Cancer Radio- and Immunotherapy CLinical Exploration Study

studies show high rates of infiltrating immune cells and PD-L1 positivity, suggesting that immunotherapy may be beneficial in this disease. Atezolizumab, targeting PD-L1, is active in several cancer types

  • 4 views
  • 22 Jan, 2021
  • 1 location
Study of Immunotherapy Combined With Chemotherapy in Locally Advanced and Metastatic Pancreatic Cancer

To evaluate the efficacy of PD-L1/CTLA4 BsAb for the second line treatment and the combination with chemotherapy for the first line treatment in pancreatic cancer

  • 0 views
  • 26 Jan, 2021
  • 1 location
Translational Study of Nivolumab in Combination With Bevacizumab for Recurrent Glioblastoma

The aim of this study is to make preliminary assessment of PD-L1 and other immune related biomarkers that might act as predictors of anti-tumor activity of Nivolumab in patients with recurrent

recurrent glioblastoma
platelet count
temozolomide
corticosteroids
measurable disease
  • 0 views
  • 25 Jan, 2021
  • 1 location
A Phase 1 Study of HLX20 a Human Monoclonal Antibody Targeting PD-L1Protein in Patients With Advanced Solid Tumors

This is an open-label, dose escalation, first-in-human study of HLX20, an anti-PD-L1 monoclonal antibody, in patients with metastatic or recurrent solid tumors who have failed standard therapy

  • 47 views
  • 22 Jan, 2021
  • 5 locations
An Exploratory Clinical Study of LDP Combined With CDP1 in Patients With Advanced Malignant Tumor

This is an exploratory clinical study of Human Anti-PD-L1 Monoclonal Antibody Injection (LDP) combined with Recombinant Anti-EGFR Human Mouse Chimeric Monoclonal Antibody Injection (CDP1) in

  • 0 views
  • 16 Feb, 2021
  • 1 location
Atezolizumab and BCG in High Risk BCG na ve Non-muscle Invasive Bladder Cancer (NMIBC) Patients (BladderGATE)

treatment have a recurrence rate at 1 and 2 years of 25 and 30% respectively after treatment with the current standard (BCG), which is clearly unsatisfactory. Programmed death ligand 1 (PD-L1) is a surface

transurethral resection
carcinoma in situ
expression by immunohistochemistry
carcinoma of the bladder
bacillus calmette-guerin
  • 0 views
  • 25 Jan, 2021
Combination Therapy for First Line Treatment of Advanced Cervical Cancer

This is a single center phase 1 trail to observe safety and efficacy of Paclitaxel plus Cisplatin\Carboplatin, PD-L1 antibody Toripalimab and Anlotinib as first-line regimen to treat the patient

  • 0 views
  • 05 Feb, 2021
  • 1 location
Effect of Anesthesia on Expression of Programmed Death-1 and Programmed Death-1 Ligand in Breast Cancer

. It has been reported that the PD-1/PD-L1 pathway could be activated by surgical stress. Hence, we instigate the effect of anesthetic technique on expression of PD1 and PD1 ligand.

  • 0 views
  • 27 Jan, 2021
  • 1 location
Study of IBI318 in Patients With Advanced Cutaneous Squamous Cell Carcinoma

The purpose of this study is to evaluate the safety and efficacy of IBI318 (anti-PD-1/PD-L1) in adult participants with metastatic (nodal or distant) cutaneous squamous cell carcinoma (CSCC), or

  • 0 views
  • 27 Jan, 2021
  • 1 location
The Selective Personalized Radio-Immunotherapy for Locally Advanced NSCLC Trial.

The goal of this study is to explore if, for locally advanced non-small cell lung cancer patients whose tumors have high levels of PD-L1 (a marker associated with benefits from immunotherapy), a

  • 6 views
  • 25 Jan, 2021
  • 1 location